| Schedule Of Segment Reporting Information |
|
|
Consumer
Products Segment |
|
|
Specialty
Pharmaceutical Segment |
|
|
Consolidated Totals |
|
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| September 30, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales,
net |
|
$ |
5,591,210 |
|
|
$ |
– |
|
|
$ |
5,591,210 |
|
| Gross profit |
|
|
3,997,649 |
|
|
|
– |
|
|
|
3,997,649 |
|
| Gain on change in derivative
liability |
|
|
10,987 |
|
|
|
– |
|
|
|
10,987 |
|
| Royalty buy-out |
|
|
– |
|
|
|
– |
|
|
|
– |
|
| Selling, general and administrative |
|
|
(4,259,725 |
) |
|
|
(51,353 |
) |
|
|
(4,311,078 |
) |
| Research
and development |
|
|
(76,520 |
) |
|
|
(102,818 |
) |
|
|
(179,338 |
) |
| Operating
loss |
|
$ |
(327,609 |
) |
|
$ |
(154,171 |
) |
|
$ |
(481,780 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| September 30, 2016: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
2,939,997 |
|
|
$ |
– |
|
|
$ |
2,939,997 |
|
| Gross profit |
|
|
1,888,949 |
|
|
|
– |
|
|
|
1,888,949 |
|
| Selling, general and administrative |
|
|
(2,952,533 |
) |
|
|
(119,908 |
) |
|
|
(3,072,441 |
) |
| Research
and development |
|
|
(292,738 |
) |
|
|
(103,500 |
) |
|
|
(396,238 |
) |
| Operating
loss |
|
$ |
(1,356,322 |
) |
|
$ |
(223,408 |
) |
|
$ |
(1,579,730 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Nine Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| September 30, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
13,437,233 |
|
|
$ |
– |
|
|
$ |
13,437,233 |
|
| Gross profit |
|
|
9,275,111 |
|
|
|
– |
|
|
|
9,275,111 |
|
| Gain on change in derivative
liability |
|
|
248,875 |
|
|
|
– |
|
|
|
248,875 |
|
| Royalty buy-out |
|
|
– |
|
|
|
(2,432,000 |
) |
|
|
(2,432,000 |
) |
| Selling, general and administrative |
|
|
(11,312,687 |
) |
|
|
(200,873 |
) |
|
|
(11,513,560 |
) |
| Research
and development |
|
|
(181,509 |
) |
|
|
(392,192 |
) |
|
|
(573,701 |
) |
| Operating
loss |
|
$ |
(1,970,210 |
) |
|
$ |
(3,025,065 |
) |
|
$ |
(4,995,275 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Nine Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| September 30, 2016: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
7,850,430 |
|
|
$ |
– |
|
|
$ |
7,850,430 |
|
| Gross profit |
|
|
5,178,911 |
|
|
|
– |
|
|
|
5,178,911 |
|
| Selling, general and administrative |
|
|
(8,904,694 |
) |
|
|
(242,717 |
) |
|
|
(9,147,411 |
) |
| Research
and development |
|
|
(658,817 |
) |
|
|
(220,781 |
) |
|
|
(879,598 |
) |
| Operating
loss |
|
$ |
(4,384,600 |
) |
|
$ |
(463,498 |
) |
|
$ |
(4,848,098 |
) |
|